PCSK9 Sponsors Looked For Regulatory Advantages In Race To Market

21 Dec 2015
Analysis

Sue Sutter @PinkSheetSutter sue.sutter@informa.com

Executive Summary

Both Sanofi/Regeneron and Amgen coveted priority review for their LDL-cholesterol-lowering agents, but the Praluent sponsors' purchase of a voucher gave them the definitive edge. Amgen found no help in the breakthrough program, with FDA twice denying designation requests for Repatha, review documents show.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical United States Clinical Trials

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS057345

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS057345

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

PCSK9 Sponsors Looked For Regulatory Advantages In Race To Market

Analysis

Executive Summary

Related Content

Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?

How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert